Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global market for peptic ulcer drugs has been characterized by steady growth, driven by the increasing prevalence of peptic ulcers and the growing demand for effective treatment options.In 2024, the market is valued at approximately USD 42.72 billion, with projections indicating it will reach USD 55.54 billion by 2031, growing at a compound annual growth rate (CAGR) of 3.80%. Peptic ulcers are open sores that develop on the lining of the stomach and the upper portion of the small intestine, leading to significant discomfort and pain. The primary symptom of a peptic ulcer is stomach discomfort, which can range from mild to severe.

Peptic ulcers can be categorized into two main types: gastric ulcers, which occur on the inside of the stomach, and duodenal ulcers, which develop on the inside of the upper portion of the small intestine (duodenum). The development of peptic ulcers is primarily associated with infection by Helicobacter pylori (H. pylori) and the long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen sodium. Contrary to popular belief, stress does not cause peptic ulcers, although it can exacerbate symptoms.

The treatment of peptic ulcers focuses on reducing the production of stomach acid, neutralizing the acid present, and protecting the ulcerated area to facilitate healing. Various medications are used in the treatment of peptic ulcers, including proton pump inhibitors (PPIs), antibiotics, H2-antagonists, and antacids. Among these, proton pump inhibitors have emerged as the most widely used treatment option, offering significant relief for patients.

Market Growth Drivers

Several factors are contributing to the growth of the peptic ulcer drugs market. The increasing adoption of over-the-counter (OTC) medications is one of the key drivers. OTC drugs offer a convenient and cost-effective option for individuals seeking treatment for peptic ulcers. Antacids, H2-receptor antagonists, and proton pump inhibitors are among the commonly available OTC treatments for peptic ulcers. The growing availability of OTC drugs is expected to drive market expansion in the coming years.

Phytotherapy, the use of medicinal plants to treat various ailments, is gaining traction as an alternative treatment option for peptic ulcers. The rising interest in alternative therapies and herbal products, particularly those derived from medicinal plants, has led to increased adoption of phytotherapy in the management of peptic ulcers. Medicinal herbs are considered a primary source of new drugs due to their potential therapeutic effects and fewer adverse reactions compared to traditional drugs.

Challenges Facing the Market

Despite the positive outlook, the peptic ulcer drugs market faces several challenges. One of the significant hurdles is the declining pipeline productivity among major players in the market. A lack of robust research and development initiatives has resulted in a reduced focus on developing novel medications for peptic ulcers. Many pharmaceutical companies are concentrating on creating prolonged-release formulations or combination therapies, but interest in developing new drugs remains limited.

Furthermore, the long-term use of proton pump inhibitors and antibiotics, common treatments for peptic ulcers, is associated with various risks. These include an increased risk of hip fractures due to reduced calcium and iron absorption, as well as an elevated risk of secondary infections caused by the depletion of natural gut flora. Side effects such as diarrhea, nutritional deficiencies, and gastrointestinal disturbances are also associated with these medications.

In addition, stringent government regulations and patent expirations pose significant barriers to market growth. These factors contribute to the overall complexity of the market Analysis and may hinder the development and commercialization of new treatments for peptic ulcers.

Regional Insights

The peptic ulcer drugs market is characterized by varying dynamics across different regions. In the United States, the market is thriving due to the high prevalence of peptic ulcers and the availability of a wide range of treatment options. The presence of multiple proton pump inhibitors in the market, such as dexlansoprazole, omeprazole, and esomeprazole, has contributed to the market's dominance in this region. The increasing incidence of H. pylori infections and the availability of effective treatment options are expected to continue driving market growth in the United States.

Germany, on the other hand, represents a significant market for peptic ulcer drugs due to the high prevalence of smoking and unhealthy lifestyle choices. The growing number of peptic ulcer patients, coupled with rising healthcare costs, is driving market demand in the country. The increasing awareness of peptic ulcers, the availability of affordable treatment options, and the improved healthcare infrastructure are also contributing factors to market growth in Germany.

China is emerging as a prominent market for peptic ulcer drugs, primarily due to its aging population. Older adults are more susceptible to gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), and the clinical manifestations of these conditions can be more severe in the elderly. The presence of risk factors such as H. pylori infection and the use of NSAIDs and aspirin further contribute to the high prevalence of peptic ulcers in China.

Competitive Analysis

The peptic ulcer drugs market is highly competitive, with leading players actively involved in research and development to launch new products and secure regulatory approvals. Companies such as Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., and AstraZeneca plc. are some of the key players in the market. These companies are focusing on product innovation and strategic partnerships to strengthen their market position.

Key Companies Covered

Daewoong Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Abbott Laboratories
AstraZeneca plc.
Cadila Healthcare Ltd.
Boehringer Ingelheim GmbH
Eisai Co. Ltd.
Yuhan Corporation
GlaxoSmithKline plc.

Key Segments Covered in Peptic Ulcer Drugs Industry Research

Product:

Proton Pump Inhibitors
Potassium-Competitive Acid Blockers (P-CABs)
Antacids
H2- Antagonists
Antibiotics
Ulcer Protective

Indication:

Gastritis
Gastric Ulcers
Duodenal Ulcers
Gastroesophageal Reflux Disease (GERD)

Distribution Channel:

Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
E-Commerce

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Peptic Ulcer Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. COVID-19 Impact Analysis
- 2.3.1. Supply
- 2.3.2. Demand
2.4. Value Chain Analysis
2.5. Porter's Five Force Analysis
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Peptic Ulcer Drugs Market Outlook, 2018 - 2031

3.1. Global Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Antacids
  - 3.1.1.2. Proton Pump Inhibitors
  - 3.1.1.3. H2-Antagonists
  - 3.1.1.4. Ulcer Protectives
  - 3.1.1.5. Antibiotics
  - 3.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
3.2. Global Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Gastric Ulcers
  - 3.2.1.2. Gastritis
  - 3.2.1.3. Duodenal Ulcers
  - 3.2.1.4. Gastroesophageal Reflux Disease (GERD)
3.3. Global Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospital Pharmacies
  - 3.3.1.2. Drug Stores
  - 3.3.1.3. Retail Pharmacies
  - 3.3.1.4. E-Commerce
3.4. Global Peptic Ulcer Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Peptic Ulcer Drugs Market Outlook, 2018 - 2031

4.1. North America Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Antacids
  - 4.1.1.2. Proton Pump Inhibitors
  - 4.1.1.3. H2-Antagonists
  - 4.1.1.4. Ulcer Protectives
  - 4.1.1.5. Antibiotics
  - 4.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
4.2. North America Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Gastric Ulcers
  - 4.2.1.2. Gastritis
  - 4.2.1.3. Duodenal Ulcers
  - 4.2.1.4. Gastroesophageal Reflux Disease (GERD)
4.3. North America Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospital Pharmacies
  - 4.3.1.2. Drug Stores
  - 4.3.1.3. Retail Pharmacies
  - 4.3.1.4. E-Commerce
4.4. North America Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Peptic Ulcer Drugs Market Outlook, 2018 - 2031

5.1. Europe Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Antacids
  - 5.1.1.2. Proton Pump Inhibitors
  - 5.1.1.3. H2-Antagonists
  - 5.1.1.4. Ulcer Protectives
  - 5.1.1.5. Antibiotics
  - 5.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
5.2. Europe Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Gastric Ulcers
  - 5.2.1.2. Gastritis
  - 5.2.1.3. Duodenal Ulcers
  - 5.2.1.4. Gastroesophageal Reflux Disease (GERD)
5.3. Europe Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospital Pharmacies
  - 5.3.1.2. Drug Stores
  - 5.3.1.3. Retail Pharmacies
  - 5.3.1.4. E-Commerce
5.4. Europe Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Peptic Ulcer Drugs Market Outlook, 2018 - 2031

6.1. Asia Pacific Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Antacids
  - 6.1.1.2. Proton Pump Inhibitors
  - 6.1.1.3. H2-Antagonists
  - 6.1.1.4. Ulcer Protectives
  - 6.1.1.5. Antibiotics
  - 6.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
6.2. Asia Pacific Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Gastric Ulcers
  - 6.2.1.2. Gastritis
  - 6.2.1.3. Duodenal Ulcers
  - 6.2.1.4. Gastroesophageal Reflux Disease (GERD)
6.3. Asia Pacific Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospital Pharmacies
  - 6.3.1.2. Drug Stores
  - 6.3.1.3. Retail Pharmacies
  - 6.3.1.4. E-Commerce
6.4. Asia Pacific Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Peptic Ulcer Drugs Market Outlook, 2018 - 2031

7.1. Latin America Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Antacids
  - 7.1.1.2. Proton Pump Inhibitors
  - 7.1.1.3. H2-Antagonists
  - 7.1.1.4. Ulcer Protectives
  - 7.1.1.5. Antibiotics
  - 7.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
7.2. Latin America Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Gastric Ulcers
  - 7.2.1.2. Gastritis
  - 7.2.1.3. Duodenal Ulcers
  - 7.2.1.4. Gastroesophageal Reflux Disease (GERD)
7.3. Latin America Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospital Pharmacies
  - 7.3.1.2. Drug Stores
  - 7.3.1.3. Retail Pharmacies
  - 7.3.1.4. E-Commerce
7.4. Latin America Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Peptic Ulcer Drugs Market Outlook, 2018 - 2031

8.1. Middle East & Africa Peptic Ulcer Drugs Market Outlook, By Product, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Antacids
  - 8.1.1.2. Proton Pump Inhibitors
  - 8.1.1.3. H2-Antagonists
  - 8.1.1.4. Ulcer Protectives
  - 8.1.1.5. Antibiotics
  - 8.1.1.6. Potassium-Competitive Acid Blockers (P-CABs)
8.2. Middle East & Africa Peptic Ulcer Drugs Market Outlook, By Indication, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Gastric Ulcers
  - 8.2.1.2. Gastritis
  - 8.2.1.3. Duodenal Ulcers
  - 8.2.1.4. Gastroesophageal Reflux Disease (GERD)
8.3. Middle East & Africa Peptic Ulcer Drugs Market Outlook, By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospital Pharmacies
  - 8.3.1.2. Drug Stores
  - 8.3.1.3. Retail Pharmacies
  - 8.3.1.4. E-Commerce
8.4. Middle East & Africa Peptic Ulcer Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Peptic Ulcer Drugs Market By Product, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Peptic Ulcer Drugs Market By Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Peptic Ulcer Drugs Market By Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Market Share Analysis, 2022
9.2. Competitive Dashboard
9.3. Company Profiles
- 9.3.1. Takeda Pharmaceutical Company Limited
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Product Portfolio
  - 9.3.1.3. Financial Overview
  - 9.3.1.4. Business Strategies and Development
- 9.3.2. Pfizer, Inc.
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Product Portfolio
  - 9.3.2.3. Financial Overview
  - 9.3.2.4. Business Strategies and Development
- 9.3.3. AstraZeneca plc.
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Product Portfolio
  - 9.3.3.3. Financial Overview
  - 9.3.3.4. Business Strategies and Development
- 9.3.4. Cadila Healthcare Ltd.
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Product Portfolio
  - 9.3.4.3. Financial Overview
  - 9.3.4.4. Business Strategies and Development
- 9.3.5. Eisai Co. Ltd.
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Product Portfolio
  - 9.3.5.3. Financial Overview
  - 9.3.5.4. Business Strategies and Development
- 9.3.6. Yuhan Corporation
  - 9.3.6.1. Company Overview
  - 9.3.6.2. Product Portfolio
  - 9.3.6.3. Financial Overview
  - 9.3.6.4. Business Strategies and Development
- 9.3.7. GSK
  - 9.3.7.1. Company Overview
  - 9.3.7.2. Product Portfolio
  - 9.3.7.3. Financial Overview
  - 9.3.7.4. Business Strategies and Development
- 9.3.8. Daewoong Pharmaceutical Co., Ltd.
  - 9.3.8.1. Company Overview
  - 9.3.8.2. Product Portfolio
  - 9.3.8.3. Financial Overview
  - 9.3.8.4. Business Strategies and Development
- 9.3.9. Abbott
  - 9.3.9.1. Company Overview
  - 9.3.9.2. Product Portfolio
  - 9.3.9.3. Financial Overview
  - 9.3.9.4. Business Strategies and Development
- 9.3.10. Boehringer Ingelheim GmbH
  - 9.3.10.1. Company Overview
  - 9.3.10.2. Product Portfolio
  - 9.3.10.3. Financial Overview
  - 9.3.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations